Comparing the current results to its competitors, Tourmaline Bio Inc reported Revenue decrease in the 2 quarter 2025 year on year by 0 %, despite the revenue increase by the most of its competitors of 5.07 %, recorded in the same quarter.
Tourmaline Bio Inc 's Comment on Competition and Industry Peers
The company is developing pacibekitug, an IL-6 inhibitor designed for potential subcutaneous dosing once every three months. This dosing schedule may offer greater convenience compared to existing anti-IL-6 agents that require intravenous administration or monthly subcutaneous dosing. The competitive landscape includes four FDA-approved IL-6 or IL-6 receptor blockers: tocilizumab (ACTEMRA®), siltuximab (SYLVANT®), sarilumab (KEVZARA®), and satralizumab-mwge (ENSPRYNG®). Additionally, three biosimilars for tocilizumab have received FDA approval, including TOFIDENCE® from Biogen and TYENNE®. The company faces competition from products with similar or different mechanisms targeting the same indications, with some competitors possessing greater resources and regulatory experience. Ongoing development of new drug candidates may impact the competitiveness or relevance of the company’s programs.
August 2, 2024
Tourmaline Bio, a pioneering company in developing therapeutics for cardiovascular health, recently unveiled the design of its Phase 2 TRANQUILITY study at the esteemed American Society of Preventive Cardiology (ASPC) Congress 2024. This pivotal event, held in location from start date to end date, gathered leading experts, clinicians, and researchers in the field of cardiology to discuss innovative approaches toward the prevention and treatment of cardiovascular diseases.The TRANQUILITY study aims to assess the efficacy and safety of Tourmaline Bio’s novel therapeutic candidates designed to improve cardiovascular health outcomes among at-risk populations. With cardiovascular disease being one of the leadin...
In a recent development, Tourmaline Bio has announced a series of exciting milestones for the clinical development of their investigational compound, TOUR006. With cutting-edge potential as a long-acting subcutaneous inhibitor of IL-6, TOUR006 shows promise as a first-line treatment in two prominent medical conditions: Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD). These upcoming advancements highlight Tourmaline Bio s dedication to improving patient outcomes and strengthening their position in the pharmaceutical industry.
Overview of Findings: One of the key highlights in Tourmaline Bio s...
Immunitybio Inc operates on a business model that focuses on developing and commercializing innovative immunotherapies and vaccines to address various diseases and medical conditions. They aim to use their broad scientific expertise, technology platforms, and strategic partnerships to advance their products and improve patient outcomes in healthcare.
Estrella Immunopharma Inc is a biotechnology company that focuses on developing innovative immunotherapies. They have a business model centered around researching, developing, and commercializing novel treatments for various diseases. Their approach includes leveraging the power of the immune system to target and eradicate diseases, with a particular emphasis on cancer.
Dyadic International Inc's business model revolves around developing and licensing proprietary microbial strains and technologies for use in the biopharmaceutical, biofuels, and industrial enzyme industries.
Ginkgo Bioworks Holdings Inc is a biotechnology company that focuses on using genetic engineering to develop new organisms for various industries. Their business model includes partnering with companies to create custom-designed organisms for applications such as fragrance production, food and beverage, agriculture, and pharmaceuticals. They generate revenue through collaborations, licensing agreements, and providing access to their platform for organism design and development.
Sources:
Tourmaline Bio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Tourmaline Bio Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
